Table 1.
Checkpoint inhibitor clinical efficacy.
| Target | Study agent | Disease type | N | Response | DoR | PFS | OS | Reference |
|---|---|---|---|---|---|---|---|---|
| CTLA-4 | Ipilimumab | R/R NHL: FL (14), DLBCL (3), MCL (1) | 18 | ORR (11%), CR (5.6%), PR (5.6%) | NA | NA | NA | Ansell et al. [2009] |
| R/R HL (s/p alloSCT) (14) | 14 | ORR (14.3%), CR (14.3), PR (0%) | NA | NA | NA | Bashey et al. [2009] | ||
| PD-1 | Pidilizumab | DLBCL (2), CLL (3), FL (1), ALCL (1), HL (1) | 8 | CR (5%), SD (33%) | NA | 25 weeks | Berger et al. [2008] | |
| R/R DLBCL (s/p ASCT) de novo (49) | 66 | ORR (51%), CR (34%), PR (17%), SD (37%) | 16 months | 0.72 years | 0.84 years | Armand et al. [2013] | ||
| Transformed DLBCL (13), PMBCL (4) | ||||||||
| Pidilizumab+Rituxan | R/R FL (32) | 32 | ORR (66%), CR (52%) | 18.8 months | NA | Westin et al. [2014] | ||
| Nivolumab | R/R HL (23) | 23 | ORR (87%), CR (17%), PR (70%), SD (13%) | at 24 weeks | 86% | NR | Ansell et al. [2015] | |
| R/R B-NHL [31] | 54 | ORR [36%–40%] | 6–81.6 weeks | Lesokhin et al. [2016] | ||||
| T-NHL (23) | ORR [15%–40%] | NA | NA | |||||
| Pembrolizumab | R/R HL (31) | 31 | ORR (65%), CR (16%), PR (48%) | >24 weeks | 46% at 52 weeks | NA | Armand et al. [2016] |
ALCL, anaplastic large-cell lymphoma; alloSCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantion; CLL, chronic lymphocytic leukemia; CR, complete response; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DLBCL, diffuse large B-cell lymphoma;
DoR, Duration of Response; FL, follicular lymphoma; HL, Hodgkin lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; NA, not available; NHL, non-Hodgkin lymphoma; NR, not reached; ORR, overall response rate; OS, overall survival; PD-1, programmed cell death 1; PFS, progression-free survival; PMBCL, primary mediastinal B-cell lymphoma; PR, partial response; R/R, relapsed/refractory; SD, stable disease; s/p, status post.